David Kirn Sells 1,922 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 1,922 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $10.02, for a total value of $19,258.44. Following the completion of the sale, the insider directly owned 1,057,231 shares in the company, valued at $10,593,454.62. This trade represents a 0.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

4D Molecular Therapeutics Trading Down 4.1%

FDMT traded down $0.40 during midday trading on Tuesday, reaching $9.31. The company’s stock had a trading volume of 1,075,089 shares, compared to its average volume of 705,181. The stock has a market cap of $486.69 million, a P/E ratio of -3.62 and a beta of 2.75. The company has a fifty day simple moving average of $9.53 and a 200 day simple moving average of $9.28. 4D Molecular Therapeutics, Inc. has a twelve month low of $3.55 and a twelve month high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The business had revenue of $3.05 million during the quarter, compared to analyst estimates of $2.59 million. 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. Sell-side analysts expect that 4D Molecular Therapeutics, Inc. will post -3.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

FDMT has been the topic of a number of research analyst reports. Royal Bank Of Canada raised their target price on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a report on Thursday, March 19th. HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Friday, March 20th. Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Jefferies Financial Group reissued a “buy” rating and set a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Monday, March 30th. Finally, Chardan Capital reissued a “buy” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $29.88.

Institutional Trading of 4D Molecular Therapeutics

Institutional investors have recently modified their holdings of the company. Dynamic Technology Lab Private Ltd acquired a new stake in shares of 4D Molecular Therapeutics during the 1st quarter worth approximately $39,000. Wexford Capital LP acquired a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter worth approximately $41,000. AQR Capital Management LLC acquired a new stake in shares of 4D Molecular Therapeutics during the 1st quarter worth approximately $46,000. Daiwa Securities Group Inc. grew its holdings in shares of 4D Molecular Therapeutics by 3,362.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after purchasing an additional 6,186 shares in the last quarter. Finally, Rangeley Capital LLC acquired a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at $48,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.